Anadys announced the presentation of results from its Phase 2b trial of ANA598 for the treatment of chronic hepatitis C virus (HCV) patients. Data from the ongoing combination study show that ANA598 added to pegylated interferon and ribavirin (current standard of care, or SOC) accelerated the rate of patients achieving undetectable levels of virus compared to placebo plus SOC, and that the antiviral response was equivalent at ANA598 200mg twice daily and ANA598 400mg twice daily. The data from the study further show a durable antiviral response through 12 weeks, with only a single patient (<2% of patients in the ANA598 arms) experiencing viral breakthrough while receiving ANA598 plus SOC.
Additionally, Anadys will later present additional data from the study showing that the addition of ANA598 to SOC conferred benefit independent of a patient’s IL-28B genotype. In patients with the IL-28B genotype most responsive to SOC (referred to as CC), ANA598 accelerated the rate of achieving undetectable levels of virus, with 82% of patients who received ANA598 plus SOC achieving undetectable levels by week 4, compared to 27% of patients who received placebo plus SOC.
ANA598 is a non-nucleoside polymerase inhibitor being developed as a direct-acting antiviral (DAA) for the treatment of chronic hepatitis C virus (HCV) infection.
For more information call (858) 530-3600 or visit www.anadyspharma.com.